Proceedings of the 2005 Australian Software Engineering Conference

Established in 1986, ASWEC is the premier technical meeting for the Australian software engineering community, and attracts a significant number of international participants. The major goal of the conference is to provide a forum for exchanging experience and new research results in software engineering. To increase the industry participation at ASWEC, we organized two separate paper tracks, which we have called Research Papers and Industry Experience Reports. These paper tracks had separate deadlines, separate program committees, separate review procedures, and separate proceedings. The Research Papers appear in these proceedings and the Industry Experience Reports will appear on a CD-Rom that will be distributed at the conference. The Research Papers track for ASWEC 2005 includes submissions from Australia and across the world. This year we received 79 submissions from 13 countries: 48 from Australia, 7 from New Zealand, 11 from Asia, 9 from Europe, and 2 each from North and South America. All papers were fully refereed by three Program Committee members. We accepted 34 papers to be presented at the conference. We are grateful to all authors who contributed to ASWEC.

N-type calcium channel blockers: Novel therapeutics for the treatment of pain

Highly selective Cav2.2 voltage-gated calcium channel (VGCC) inhibitors have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Cone snail venoms provided the first drug in class with FDA approval granted in 2005 to Prialt (ω-conotoxin MVIIA, Elan) for the treatment of neuropathic pain. Since this pioneering work, major efforts underway to develop alternative small molecule inhibitors of Cav2.2 calcium channel have met with varied success. This review focuses on the properties of the Cav2.2 calcium channel in different pain states, the action of ω-conotoxins GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved Cav2.2 calcium channel therapeutics, and finally the development of small molecules for the treatment of chronic pain.

Access to death certificates: What should research ethics committees require for approval?

PURPOSE: To present and discuss the reactions of research ethics committees (RECs) in a number of countries when asked for approval Of a study requiring access to death certificates to identify the physicians signing the certificates and to send them a four-page questionnaire about medical decisions made at the patient's end-of-life that could possibly have hastened death. METHODS: A simple questionnaire were sent to the responsible national investigator in an international study (Australia, Belgium, Denmark, Italy, the Netherlands, Sweden, Switzerland) asking about the interactions between the national research group and the national/regional REC(s). RESULTS: Different laws or guidelines were used by the RECs. Denmark, the Netherlands, and Switzerland did not require an application to a REC. In Australia and Sweden, the RECs wanted changes in the research protocol, and one national research group had to refrain from publishing its results because the attrition rate became too high, probably due to the required changes in the protocol. RECOMMENDATIONS: Generally, similar demands from all RECs in relation to one project are strongly desirable. In epidemiological research, in which Voluntary completion of an anonymous questionnaire demonstrates consent, additional prior informed consent about being approached should not be required.